Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: Lessons from a stopped trial?

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 471-473

  Kellner, Michael ^a   Muhtz, Christoph ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PLACEBO; SERTRALINE; TOPIRAMATE; TRAZODONE; ZIPRASIDONE; PIPERAZINE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; THIAZOLE DERIVATIVE;

ADD ON THERAPY; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG POTENCY; FATIGUE; HEART PALPITATION; HUMAN; JAW RIGIDITY; LETTER; MICTURITION DISORDER; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA; POSTTRAUMATIC DIAGNOSTIC SCALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; REMISSION; TREATMENT RESPONSE; TREMOR; VERTIGO; VISUAL IMPAIRMENT; ADULT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; ETHICS; FEMALE; MALE; MIDDLE AGED; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRESS DISORDERS, POST-TRAUMATIC;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC; THIAZOLES;

EID: 77955128047     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e79600     Document Type: Letter

References (10)

1. Stein DJ, Cloitre M, Nemeroff CB, et al. Cape Town consensus on posttraumatic stress disorder. CNS Spectr. 2009; 14(suppl 1):52-58.
2. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67:1327-1340.
3. Crane DL. Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders. CNS Spectrums. 2005;10: 176-179.
4. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007;68:1071-1077.
5. Wilner KD, Anziano RJ, Johnson AC, et al. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002;22: 206-210.
6. Frecska E, Keresztes M, Gaszner G. Misdiagnosed PTSD and zeldox pharmacotherapy in a case of political prisoner. Neuropsychopharmacol Hung. 2004;6:221-223.
7. Siddiqui Z, Marcil WA, Bhatia SC, et al. Ziprasidone therapy for post-traumatic stress disorder. J Psychiatry Neurosci. 2005;30: 430-431.
8. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003; 17:517-538.
9. Cates ME. ZiprasidoneVnot an option for serotonin syndrome. CMAJ. 2003;169: 1147-1148.
10. Bonne O, Bain E, Neumeister A, et al. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am J Psychiatry. 2005;162: 383-385.